NAV

Hydrogen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Hydrogen
DrugBank Accession Number
DB15127
Background

Hydrogen is under investigation in clinical trial NCT02830854 (Molecular Hydrogen for Cognitive Function and Performance in Elderly).

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 2.016
Monoisotopic: 2.015650064
Chemical Formula
H2
Synonyms
  • Dihydrogen
  • Molecular hydrogen
  • Protium

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
7YNJ3PO35Z
CAS number
1333-74-0
InChI Key
UFHFLCQGNIYNRP-UHFFFAOYSA-N
InChI
InChI=1S/H2/h1H
IUPAC Name
dihydrogen
SMILES
[H][H]

References

General References
Not Available
Human Metabolome Database
HMDB0001362
KEGG Compound
C00282
ChemSpider
762
RxNav
5497
ChEBI
18276
Wikipedia
Hydrogen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentCoronary Artery Disease (CAD) / Percutaneous Coronary Intervention (PCI)1
3CompletedTreatmentOnychomycosis1
3RecruitingTreatmentLow Grade Astrocytomas / Low Grade Glioma (LGG) / Metastatic Low Grade Astrocytomas / Metastatic Low Grade Glioma (LGG)1
3RecruitingTreatmentLow Grade Glioma (LGG) / Neurofibromatosis Type 1 / Visual Pathway Glioma1
3RecruitingTreatmentRecurrent Low Grade Astrocytoma / Recurrent WHO Grade 2 Glioma / Refractory Low Grade Astrocytoma / Refractory Low Grade Glioma / Refractory WHO Grade 1 Glioma1
3Unknown StatusTreatmentEvidence of Liver Transplantation1
2Active Not RecruitingTreatmentAdvanced Malignant Solid Tumor / Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma / Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Malignant Solid Neoplasm / Recurrent Neuroblastoma / Refractory Malignant Solid Neoplasm / Refractory Neuroblastoma / Refractory Non-Hodgkin's lymphoma / Refractory, primary Central Nervous System Neoplasm1
2Active Not RecruitingTreatmentCutaneous Neurofibromas / Neurofibromatosis Type 1 / Optic Nerve Glioma1
2CompletedTreatmentBorderline Ovarian Serous Tumor / Low Grade Ovarian Serous Adenocarcinoma / Micropapillary Serous Carcinoma / Primary Peritoneal Carcinoma / Primary Peritoneal Low Grade Serous Adenocarcinoma / Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor1
2CompletedTreatmentKRAS NP_004976.2:p.G12R / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer AJCC v6 and v71

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Physiological Charge0Chemaxon
Hydrogen Acceptor Count0Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area0 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity0 m3·mol-1Chemaxon
Polarizability0.74 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at May 20, 2019 14:52 / Updated at May 10, 2021 12:36